Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
1–17
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male or female children ≥15 months to \<18 years of age at the time of consent.
Healthy children determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.
For children \<5 years of age, written documentation of receipt of at least 3 doses of 13vPnC. The last dose of 13vPnC must have been administered \>2 months before enrolment into the study
You may not be if
History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)
Major known congenital malformation or serious chronic disorder
Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results
Previous vaccination with any investigational pneumococcal vaccine or with PPSV23, or planned receipt through study participation
Cohorts 3 and 4: Pregnant or breastfeeding female participants
Clareo Health | Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
